No, MHAN had a couple of products in their pipeline, but the main one was Hedrin, Licensed from a Europe firm in a US JV with MHAN.
They took over another private firm that had 3-4 drugs in their pipeline, but MHAN failed to get further funding and was taken over and R/M in to the current firm, to take the current firm and major products public.
All of the product candidates, about 6-7 of them that MHAN had in late 2011, have obviously been shelved, but could be spun off or sold at some point to raise cash.
Market Data 
Markets 
AI
